Literature DB >> 26718108

Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care.

Robert L Coleman1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26718108     DOI： 10.1038/nrclinonc.2015.225

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

Authors:  Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

3.  Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.

Authors:  Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver
Journal:  J Am Coll Surg       Date:  2015-02-14       Impact factor: 6.113

4.  Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.

Authors:  Richard Wyn Griffiths; Ying-Kiat Zee; Saran Evans; Claire L Mitchell; Gireesh C Kumaran; Richard S Welch; Gordon C Jayson; Andrew R Clamp; Jurjees Hasan
Journal:  Int J Gynecol Cancer       Date:  2011-01       Impact factor: 3.437

5.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Takafumi Ikeda; Manabu Minami; Atsushi Kawaguchi; Toshinori Murayama; Masashi Kanai; Yukiko Mori; Shigemi Matsumoto; Shunsuke Chikuma; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Akihiko Ueda; Yuko Hosoe; Satoshi Morita; Masayuki Yokode; Akira Shimizu; Tasuku Honjo; Ikuo Konishi
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

6.  Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.

Authors:  Joseph A Dottino; William A Cliby; Evan R Myers; Robert E Bristow; Laura J Havrilesky
Journal:  Gynecol Oncol       Date:  2015-06-10       Impact factor: 5.482

Review 7.  Prognostic and predictive markers for the new immunotherapies.

Authors:  Kathleen M Mahoney; Michael B Atkins
Journal:  Oncology (Williston Park)       Date:  2014-11       Impact factor: 2.990

8.  Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.

Authors:  Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Whole-genome characterization of chemoresistant ovarian cancer.

Authors:  Ann-Marie Patch; Elizabeth L Christie; Dariush Etemadmoghadam; Dale W Garsed; Joshy George; Sian Fereday; Katia Nones; Prue Cowin; Kathryn Alsop; Peter J Bailey; Karin S Kassahn; Felicity Newell; Michael C J Quinn; Stephen Kazakoff; Kelly Quek; Charlotte Wilhelm-Benartzi; Ed Curry; Huei San Leong; Anne Hamilton; Linda Mileshkin; George Au-Yeung; Catherine Kennedy; Jillian Hung; Yoke-Eng Chiew; Paul Harnett; Michael Friedlander; Michael Quinn; Jan Pyman; Stephen Cordner; Patricia O'Brien; Jodie Leditschke; Greg Young; Kate Strachan; Paul Waring; Walid Azar; Chris Mitchell; Nadia Traficante; Joy Hendley; Heather Thorne; Mark Shackleton; David K Miller; Gisela Mir Arnau; Richard W Tothill; Timothy P Holloway; Timothy Semple; Ivon Harliwong; Craig Nourse; Ehsan Nourbakhsh; Suzanne Manning; Senel Idrisoglu; Timothy J C Bruxner; Angelika N Christ; Barsha Poudel; Oliver Holmes; Matthew Anderson; Conrad Leonard; Andrew Lonie; Nathan Hall; Scott Wood; Darrin F Taylor; Qinying Xu; J Lynn Fink; Nick Waddell; Ronny Drapkin; Euan Stronach; Hani Gabra; Robert Brown; Andrea Jewell; Shivashankar H Nagaraj; Emma Markham; Peter J Wilson; Jason Ellul; Orla McNally; Maria A Doyle; Ravikiran Vedururu; Collin Stewart; Ernst Lengyel; John V Pearson; Nicola Waddell; Anna deFazio; Sean M Grimmond; David D L Bowtell
Journal:  Nature       Date:  2015-05-28       Impact factor: 49.962
  10 in total
  8 in total

1.  Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials.

Authors:  Carmen Radecki Breitkopf; Jennifer L Ridgeway; Gladys B Asiedu; Katherine Carroll; Meaghan Tenney; Aminah Jatoi
Journal:  Clin Trials       Date:  2016-06-27       Impact factor: 2.486

2.  Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival.

Authors:  Nicholas Cardillo; Douglas Russo; Andreea Newtson; Henry Reyes; Yasmin Lyons; Eric Devor; David Bender; Michael J Goodheart; Jesus Gonzalez-Bosquet
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

3.  Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019.

Authors:  Yongming Li; Yudong Chen; Mulan Wei; Chaohe Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

4.  The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.

Authors:  Linjie Zhao; Wei Wang; Shuang Huang; Zhengnan Yang; Lian Xu; Qilian Yang; Xiu Zhou; Jinjin Wang; Qiuhong Shen; Chenlu Wang; Xiaobing Le; Min Feng; Nianxin Zhou; Wayne Bond Lau; Bonnie Lau; Shaohua Yao; Tao Yi; Xin Wang; Xia Zhao; Yuquan Wei; Shengtao Zhou
Journal:  Genome Biol       Date:  2018-03-16       Impact factor: 13.583

5.  Real-time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin.

Authors:  Yingzhao Liu; Yan Feng; Hongmei Liu; Jianyong Wu; Yong Tang; Qi Wang
Journal:  Oncol Lett       Date:  2018-07-27       Impact factor: 2.967

6.  VISTA expressed in tumour cells regulates T cell function.

Authors:  Kumuluzi Mulati; Junzo Hamanishi; Noriomi Matsumura; Kenji Chamoto; Nathan Mise; Kaoru Abiko; Tsukasa Baba; Ken Yamaguchi; Naoki Horikawa; Ryusuke Murakami; Mana Taki; Kharma Budiman; Xiang Zeng; Yuko Hosoe; Miyuki Azuma; Ikuo Konishi; Masaki Mandai
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

Review 7.  Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion.

Authors:  Wanjia Tian; Ningjing Lei; Junying Zhou; Mengyu Chen; Ruixia Guo; Bo Qin; Yong Li; Lei Chang
Journal:  Cell Death Dis       Date:  2022-01-18       Impact factor: 8.469

8.  The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.

Authors:  Anaïs Wambecke; Mohammad Ahmad; Pierre-Marie Morice; Bernard Lambert; Louis-Bastien Weiswald; Mégane Vernon; Nicolas Vigneron; Edwige Abeilard; Emilie Brotin; Martin Figeac; Pascal Gauduchon; Laurent Poulain; Christophe Denoyelle; Matthieu Meryet-Figuiere
Journal:  Mol Oncol       Date:  2021-07-13       Impact factor: 6.603
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.